ReviewHNO2026
[Outcome of the geriatric head and neck cancer patient].
Review in HNO, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDemographic changes are influencing the spectrum of patients seen in ear, nose, and throat medicine. Geriatric tumor patients vary greatly in terms of their comorbidities and physical function, requiring an adaptation of typical treatment concepts.
objectiveThe aim of this work was to examine the current prospects for treating head and neck tumors in geriatric patients, with a focus on survival, functionality, and quality of life. MATERIALS AND
methodsA narrative literature search and discussion were conducted, considering the aforementioned question. The graphics were created using Windows PowerPoint 2019 (Microsoft, Redmond, WA, USA), Servier Medical Art (Servier, Munich, Germany).
resultsPatients with head and neck tumors who are older than 70 years survive for significantly shorter periods than younger patients (under 70 years), with a median survival time of 35 months. They generally require comprehensive, personalized treatment plans that extend well beyond acute oncological intervention to achieve optimal therapeutic outcomes.
conclusionThe increased complexity of cases involving geriatric patients, coupled with their growing numbers, requires expanded collaboration with geriatric screening and intervention programs, the development of the necessary infrastructure, staff training, and the inclusion of this patient group in future studies.
Indexed as
Identifiers
41915200What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.